UNSPSC 51181539: Gliamilide

This classification denotes an anti-diabetic agent with the molecular formula C23H33N5O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OTY52EM5B2, chemically known as 3-pyridinecarboxamide, n-(2-(1-(((((bicyclo(2.2.1)-hept-5-en-2-ylmethyl)amino)carbonyl)amino)sulfonyl)-4-piperidinyl)ethyl)-2-methoxy-, endo but generally known as gliamilide, which bears US NIH Compound Identifier 3037231. European Medicines Agency schedules Gliamilide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07915MIG.

UNSPSC 51181539 Gliamilide, a Commodity code, encompasses diabetes medications supplied through cooperative purchasing agreements to state and local government facilities. State and local governments buy branded and generic diabetes pharmaceuticals through multi-state cooperative contracts that aggregate demand across participating jurisdictions and route products through authorized pharmaceutical wholesalers. Issuing bodies include state procurement offices administering multistate cooperative purchasing alliances on behalf of participating state agencies, counties, cities, and other public facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary sourcing mechanism for this category, consolidating pharmaceutical procurement across member states and local government entities and centralizing vendor management, pricing negotiation, and supply-chain compliance oversight.

The code shows recent activity concentrated in the Upper Midwest and Pacific Northwest, with MMCAP's multistate alliance including Oregon and other participating states. MMCAP issued a Request for Proposal (S1070000015802) on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026. The RFP seeks manufacturers willing to supply identified pharmaceutical products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with products available by May 15, 2026, and contracts effective July 1, 2026. Vendor evaluation prioritizes price competitiveness (75 percent), fixed pricing (10 percent), EDI capability (5 percent), administrative-fee compliance (5 percent), and administrative data format compliance (5 percent). Vendors must certify current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance, maintain relationships with at least two authorized wholesalers, carry professional liability insurance of $2,000,000 and commercial general liability of $5,000,000 per occurrence, and accept a 3 percent administrative fee on all contract purchases.